Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update
Second Quarter 2024 and Recent Developments:
- Announced completion of enrollment in its Tailwind Phase 2 clinical study of inhaled AP-PA02 in patients with Non-Cystic Fibrosis Bronchiectasis (NCFB) and chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infection. The last patient final follow-up visit occurred on
August 7 . Armata anticipates topline data from the Tailwind study in the second half of 2024. - Received
$5.25 million of additional non-dilutive funding from theU.S. Department of Defense pursuant to a previously-announced grant. The award is partially supporting advancement of the Phase 2a portion of the diSArm study of intravenous AP-SA02 as a potential treatment for Staphylococcus aureus (S. aureus) bacteremia. - Further advanced bacteriophage science through presentations and publications:
- Delivered a presentation on advancing bacteriophage therapy at Viruses of Microbes 2024, which was held
July 15-19, 2024 , in Cairns,Australia .
- Delivered a presentation on advancing bacteriophage therapy at Viruses of Microbes 2024, which was held
- Completed the build-out of its advanced biologics manufacturing facility with five current good manufacturing practice ("cGMP") clean rooms, including a state-of-the-art automated fill and finish suite.
"During the second quarter and subsequent period, we made meaningful progress across both of our clinical programs, keeping us on track to potentially initiate pivotal studies next year," stated Dr.
"For AP-SA02, we continued to advance our Phase 2a diSArm study of intravenous AP-SA02 as a potential treatment for S. aureus bacteremia. We are grateful to the
"Also, during the second quarter, we completed the build-out of our state-of-the-art cGMP manufacturing facility, giving us the ability to support our late-stage clinical trials, potential partnerships, and potential commercial production."
"Our mission has long been the execution of rigorously designed, randomized clinical studies that demonstrate the safety and efficacy of our multi-phage candidates to support eventual registration, and I am very pleased with our sustained progress during the second quarter and through the first half of the year,"
Second Quarter 2024 Financial Results
Grant Revenue. The Company recognized no grant revenue for the three months ended
Research and Development. Research and development expenses for the three months ended
General and Administrative. General and administrative expenses for the three months ended
Loss from Operations. Loss from operations for the three months ended
Cash and Equivalents. As of
As of
About
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.
Forward Looking Statements
This communication contains "forward-looking" statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to Armata's future financial performance and involve known and unknown risks, uncertainties and other factors which may cause Armata's actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions. These forward-looking statements reflect management's beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties including risks related to Armata's development of bacteriophage-based therapies; ability to staff and maintain its production facilities under fully compliant current Good Manufacturing Practices; ability to meet anticipated milestones in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics; ability to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata's estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption "Risk Factors" and elsewhere in Armata's filings and reports with the
Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Media Contacts:
At Armata:
ir@armatapharma.com
310-665-2928
Investor Relations:
jallaire@lifesciadvisors.com
212-915-2569
|
Condensed Consolidated Balance Sheets (in thousands) (unaudited) |
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
Assets |
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
26,405 |
|
$ |
13,523 |
|
|
Prepaid expenses and other current assets |
|
|
3,256 |
|
|
2,265 |
|
|
Other receivables |
|
|
1,242 |
|
|
3,363 |
|
|
Total current assets |
|
|
30,903 |
|
|
19,151 |
|
|
Property and equipment, net |
|
|
13,474 |
|
|
12,559 |
|
|
Operating lease right-of-use asset |
|
|
43,671 |
|
|
44,717 |
|
|
Intangible assets, net |
|
|
13,746 |
|
|
13,746 |
|
|
Other long term assets |
|
|
6,519 |
|
|
8,190 |
|
|
Total assets |
|
$ |
108,313 |
|
$ |
98,363 |
|
|
|
|
|
|
|
|
|
|
|
Liabilities and stockholders' deficit |
|
|
|
|
|
|
|
|
Total current liabilities |
|
$ |
123,181 |
|
$ |
16,461 |
|
|
Long-term debt |
|
|
— |
|
|
82,307 |
|
|
Operating lease liabilities, net of current portion |
|
|
28,156 |
|
|
28,583 |
|
|
Deferred tax liability |
|
|
3,077 |
|
|
3,077 |
|
|
Total liabilities |
|
|
154,414 |
|
|
130,428 |
|
|
Stockholders' deficit |
|
|
(46,101) |
|
|
(32,065) |
|
|
Total liabilities and stockholders' deficit |
|
$ |
108,313 |
|
$ |
98,363 |
|
|
Condensed Consolidated Statements of Operations (in thousands, except share and per share data ) (unaudited) |
|||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Six Months Ended |
|
||||||||
|
|
|
|
|
|
|
||||||||
|
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
|
||||
|
Grant revenue |
|
$ |
— |
|
$ |
980 |
|
$ |
966 |
|
$ |
1,776 |
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
8,475 |
|
|
8,259 |
|
|
16,491 |
|
|
17,863 |
|
|
General and administrative |
|
|
3,439 |
|
|
2,350 |
|
|
6,617 |
|
|
4,888 |
|
|
Total operating expenses |
|
|
11,914 |
|
|
10,609 |
|
|
23,108 |
|
|
22,751 |
|
|
Operating loss |
|
|
(11,914) |
|
|
(9,629) |
|
|
(22,142) |
|
|
(20,975) |
|
|
Interest income |
|
|
221 |
|
|
46 |
|
|
273 |
|
|
64 |
|
|
Interest expense |
|
|
(2,718) |
|
|
— |
|
|
(4,538) |
|
|
— |
|
|
Change in fair value of convertible debt |
|
|
23,397 |
|
|
6,036 |
|
|
10,372 |
|
|
2,874 |
|
|
Net income (loss) |
|
$ |
8,986 |
|
$ |
(3,547) |
|
$ |
(16,035) |
|
$ |
(18,037) |
|
|
Per share information: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share, basic |
|
$ |
0.25 |
|
$ |
(0.10) |
|
$ |
(0.44) |
|
$ |
(0.50) |
|
|
Weighted average shares outstanding, basic |
|
|
36,154,521 |
|
|
36,068,130 |
|
|
36,139,873 |
|
|
36,056,649 |
|
|
Net loss per share, diluted |
|
$ |
(0.25) |
|
$ |
(0.17) |
|
$ |
(0.45) |
|
$ |
(0.50) |
|
|
Weighted average shares outstanding, diluted |
|
|
58,246,626 |
|
|
56,544,698 |
|
|
58,231,978 |
|
|
36,056,649 |
|
|
Condensed Consolidated Statements of Cash Flows (in thousands) (unaudited) |
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended |
|
||||
|
|
|
2024 |
|
2023 |
|
||
|
Operating activities: |
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(16,035) |
|
$ |
(18,037) |
|
|
Adjustments required to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization expense |
|
|
632 |
|
|
458 |
|
|
Stock-based compensation expense |
|
|
1,869 |
|
|
1,118 |
|
|
Change in fair value of convertible debt |
|
|
(10,372) |
|
|
(2,874) |
|
|
Non-cash interest expense |
|
|
4,538 |
|
|
— |
|
|
Change in right-of-use asset |
|
|
960 |
|
|
— |
|
|
Changes in operating assets and liabilities: |
|
|
(2,353) |
|
|
(10,295) |
|
|
Net cash used in operating activities |
|
|
(20,761) |
|
|
(29,630) |
|
|
Investing activities: |
|
|
|
|
|
|
|
|
Purchases of property and equipment |
|
|
(1,616) |
|
|
(2,232) |
|
|
Net cash used in investing activities |
|
|
(1,616) |
|
|
(2,232) |
|
|
Financing activities: |
|
|
|
|
|
|
|
|
Proceeds from issuance of convertible debt, net of issuance costs |
|
|
— |
|
|
29,226 |
|
|
Proceeds from issuance of long-term debt, net of issuance costs |
|
|
34,889 |
|
|
— |
|
|
Proceeds from exercise of stock options |
|
|
130 |
|
|
— |
|
|
Net cash provided by financing activities |
|
|
35,019 |
|
|
29,226 |
|
|
Net increase (decrease) in cash, cash equivalents and restricted cash |
|
|
12,642 |
|
|
(2,636) |
|
|
Cash, cash equivalents and restricted cash, beginning of period |
|
|
19,243 |
|
|
20,812 |
|
|
Cash, cash equivalents and restricted cash, end of period |
|
$ |
31,885 |
|
$ |
18,176 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended |
|||||
|
|
|
2024 |
|
2023 |
|||
|
Cash and cash equivalents |
|
$ |
26,405 |
|
$ |
12,456 |
|
|
Restricted cash |
|
|
5,480 |
|
|
5,720 |
|
|
Cash and restricted cash |
|
$ |
31,885 |
|
$ |
18,176 |
|
View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-announces-second-quarter-2024-results-and-provides-corporate-update-302219948.html
SOURCE
